CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 Shares of StockDefense World · 6 days ago
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerGlobeNewsWire · Oct 13, 2026
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmGuruFocus · Oct 12, 2026
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPRNewsWire · Oct 12, 2026
Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $72,980.00 in StockDefense World · Sep 20, 2026
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.66 | -$0.90 | Miss |
| May 8, 2026 | -$0.58 | -$0.71 | Miss |
| Feb 27, 2026 | -$0.61 | -$0.51 | Beat |
| Nov 14, 2025 | -$0.56 | -$0.57 | Miss |
| Aug 8, 2025 | -$0.49 | -$0.54 | Miss |
| May 13, 2025 | -$0.39 | -$0.45 | Miss |